Soligenix starts Phase 2 trial of SGX945 for Behçet's Disease, aiming to enroll 25 patients and report results by mid-2025.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

Behçet's disease (BD) is a systemic large-vessel vasculitis characterized by a wide clinical spectrum including recurrent oral and genital ulcerations, uveitis, and vascular, neurological ...

The cause of Behcet’s syndrome may be autoimmune. Symptoms include inflamed eyes, rashes, mouth and genital sores. There are no specific tests for a definitive diagnosis but classification ...

Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet ...

Considering taking supplements to treat behcet disease? Below is a list of common natural remedies used to treat or reduce the symptoms of behcet disease. Follow the links to read common uses ...

Professor Fortune’s holistic approach to patient care changes the lives of Behçet’s syndrome patients. Behçet’s syndrome is a rare chronic condition that causes inflammation of the blood vessels and ...

COVID-19 survivors may develop autoimmune conditions long-term, with risks varying by severity and vaccination status, ...

29 Oct - ANGERME member Yuki Hirayama recently revealed that she has been diagnosed with the rare disease called Behcet's ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J., Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...